Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications

BMC Research Notes

Paolo Zola²  Maria Flavia Di Renzo¹  Annalisa Luchin³  Cosimo Martino¹  Cristiana Marchese³  Annamaria Ferrero²  Roberto Passera⁴  Luca Fuso²  Anna Surbone² 

[1] Department of Oncological Sciences of the University of Torino, Institute for Cancer Research ant treatment Candiolo, Turin, Italy;Unit of Gynecologic Oncology, Department of Gynecology and Obstetrics of the University of Torino at Azienda Ospedaliera Ordine Mauriziano, Largo Turati 62, Turin, Italy;Clinical Chemistry Laboratory, Azienda Ospedaliera Ordine Mauriziano, Turin, Italy;Nuclear Medicine Unit, University of Torino at San Giovanni Battista Hospital, Turin, Italy

关键词: Epithelial ovarian cancer;    Nadroparin;    Pharmacokinetics;    LMWH;    HGF;   

Others  :  1165639
DOI  :  10.1186/1756-0500-5-517

 received in 2012-07-26, accepted in 2012-09-17,  发布年份 2012

【 摘 要 】

Background

Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in human ovarian cancer cells. Because of potential pitfalls of HGF exogenous administration, we investigated whether HGF serum concentration might be alternatively raised in vivo by administering low molecular weight heparin (LMWH).

Methods

The main HGF pharmacokinetic parameters were evaluated following acute and chronic LMWH treatment. First, women, operated on for gynaecological tumors, were treated with a single dose of calcium nadroparin and studied for 12 hours. Next, women operated on for benign or malignant gynaecological tumors were treated daily with calcic nadroparin for one month. Subsequently, the biological activity of the measured HGF serum levels was tested in assays of ovarian cancer cell sensitization to drugs.

Results

In the short-term treated group, median HGF AUC_ss, C_max and C_average were about four-fold that of the control group, whereas C_min was three-fold. In the patients treated chronically median HGF serum levels rose about six-fold in the first week, and decreased but remained significantly higher after one month. The pharmacokinetic of nadroparin-dependent HGF increase were similar in the two groups. The HGF concentrations measured after both acute and chronic treatment were found to be effective in sensitising ovarian cancer cells to chemotherapeutics.

Conclusions

This study raises the possibility of using LMWH to increase HGF serum concentration and to take advantage of its biological activities. In particular, nadroparin might be used as a chemo-potentiating agent in epithelial cell ovarian carcinoma through its action on HGF serum concentration.

Trial registration

ClinicalTrials.gov ID: NCT01523652

【 授权许可】

   
2012 Surbone et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Matsumoto K, Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996, 119:591-600.
• [2]Grant DS, Kleinman HK, Goldberg ID: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993 Mar 1, 90(5):1937-41.
• [3]Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12):915-25.
• [4]Kusumoto K, Ido A, Moriuchi A: Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. Int J Mol Med. 2006 Mar, 17(3):503-9.
• [5]Hamanoue M, Kawaida K, Takao S: Rapid and marked induction of hepatocyte growth factor during liver regeneration after ischemic or crush injury. Hepatology 1992 Dec, 16(6):1485-92.
• [6]Hwang TH, Yoon BC, Jeong JS, Seo SY, Lee HJ: A single administration of adenoviral-mediated HGF cDNA permits survival of mice from acute hepatic failure. Life Sci 2003 Jan 3, 72(7):851-61.
• [7]Bates CM, Lin F: Future strategies in the treatment of acute renal failure: growth factors, stem cells, and other novel therapies. Curr Opin Pediatr 2005, 17(2):215-20. Review
• [8]Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001 Jun, 59(6):2023-38. Review
• [9]Jin H, Wyss JM, Yang R, Schwall R: The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004, 10(20):2525-33. Review
• [10]Maggiora P, Lorenzato A, Fracchioli S: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003 Aug 15, 288(2):382-9.
• [11]Boccaccio C, Comoglio PM: Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6(8):637-45.
• [12]Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005 Jan, 53(1):35-69.
• [13]Zillhardt M, Christensen JG, Lengyel E: An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 2010, 12(1):1-10.
• [14]Rasola A, Anguissola S, Ferrero N: Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004, 64(5):1744-50.
• [15]Coltella N, Rasola A, Nano E: p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer 2006, 118(12):2981-90.
• [16]Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF: The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007, 13(7):2191-8.
• [17]Seidel C, Hjorth-Hansen H, Bendz B: Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol 1999, 105(3):641-7.
• [18]Salbach PB, Bruckmann M, Turovets O, Kreuzer J, Kubler W, Walter-Sack I: Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000, 50(3):221-6.
• [19]Borawski J, Naumnik B, Mysliwiec M: Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin. Kidney Int 2003, 64(6):2229-37.
• [20]Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S: Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999, 255(1):80-7.
• [21]Kinoshita M, Miyamoto T, Ohashi N, Sasayama S, Matsumori A: Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 2002, 106(24):3133-8.
• [22]Sakiyama R, Fukuta K, Matsumoto K, Furukawa M, Takahashi Y, Nakamura T: Stimulation of Hepatocyte Growth Factor Production by Heparin-derived Oligosaccharides. J Biochem (Tokyo) 2007, 141(5):653-660. Epub 2007 Feb 22
• [23]Lebeau B, Chastang C, Brechot JM: Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994, 74(1):38-45.
• [24]Altinbas M, Coskun HS, Er O: A randomized clinical trial of combination chemotherapy with and without low molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004, 2(8):1266-71.
• [25]Robert F, Busby E, Marques MB, Reynolds RE, Carey DE: Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 2003, 42(2):237-45.
• [26]Kakkar AK, Levine MN, Kadziola Z: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22(10):1944-8.
• [27]Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000, 26(Suppl 1):31-8.
• [28]Rydzewska-Rosołowska A, Borawski J, Myśliwiec M: Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins. Ren Fail 2009, 31(9):791-7.
• [29]Naka D, Ishii T, Shimomura T, Hishida T, Hara H: Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp. Cell Res 1993 Dec, 209(2):317-24.
• [30]Matsumoto K: Nakamura T Heparin functions as a hepatotrophic factor by inducing production of hepatocyte growth factor. Biochem Biophys Res Commun 1996, 227(2):455-61.
• [31]Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL, Fugedi P, Chamow SM, Schwall RH, Stack RJ: Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 1995, 270(28):16871-8.